-
Mashup Score: 13
As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up. Yawning gaps have spread out between data acquisition, scientific learning, and translation into tangible benefits for people suffering from diseases like Alzheimer’s. Closing these gaps is the goal of the Artificial Intelligence Biomedical Research Scientist Initiative, which is forming a consortium of
Source: www.alzforum.orgCategories: General Medicine NewsTweet
-
Mashup Score: 1
Scientists consider Alzheimer’s disease to be a secondary tauopathy induced by amyloid plaques. Given that Aβ and tau start aggregating in different regions of the brain, how does one set off the other? Combining functional MRI, Aβ-PET, and tau-PET, scientists led by Nicolai Franzmeier, Ludwig-Maximilians University in Munich, found that amyloid intensifies connectivity between tangle epicenters in the medial temporal lobe and areas in the cortex that are destined to fall prey to these fibrils later. The
Source: www.alzforum.orgCategories: General Medicine News, Hem/OncsTweet-
Plaques Spur Spread of Tangles by Sending Synapses into Overdrive https://t.co/yBoCaUyglR via @SebRoemer et al https://t.co/LEG3M10bog
-
-
Mashup Score: 3
How do astrocytes react to Alzheimer’s disease pathology? It’s complicated, according to the largest single-nuclei RNA-Seq study of these cells published thus far. Scientists led by Sudeshna Das at Massachusetts General Hospital, Boston, in collaboration with scientists at AbbVie, characterized more than 600,000 astrocytes from five regions of 32 postmortem brains that spanned the gamut from low to high AD neuropathology. In the November 11 Nature Neuroscience, the researchers detailed seven astrocyte
Source: www.alzforum.orgCategories: General Medicine News, General HCPsTweet-
#Astrocytes Mount Complex Responses to AD. They Change Over Time https://t.co/7FAf7QUyh8. @alzforum Astrocyte transcriptomic changes along the spatiotemporal progression of #Alzheimer’s disease https://t.co/50EmZlMbs0 @NatureNeuro #snRNAseq #pTau #Aβ #NFT #Astrogliosis… https://t.co/fstOqbgflI https://t.co/EF2gtHKz6s
-
-
Mashup Score: 0Just as Sharp: MRI Scans at Triple the Speed | ALZFORUM - 5 month(s) ago
What if there were a way to triple the speed of MRI scans without losing resolution? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Spain, Miguel Rosa-Grilo of University College London presented just such an option. By leveraging recent advances in scanning technology, his group cut the time needed for diagnostic structural MRIs by two-thirds, with no measurable loss of quality. Shown side-by-side comparisons of scans done by the new versus old
Source: www.alzforum.orgCategories: General Medicine News, General HCPsTweet-
Just as Sharp: #MRI Scans at Triple the Speed https://t.co/tRyCnm24YJ
-
-
Mashup Score: 7
Lecanemab has been in clinical use in the U.S. for nearly two years, and in Japan for not quite a year. How is it going? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 through November 1 in Madrid, Spain, speakers offered a snapshot. In the U.S., about 9,000 people have been treated, most of them white city dwellers. Clinicians are following the recommended schedule of MRIs for safety monitoring, and ARIA rates have been comparable to those in the trials, despite these real-world
Source: www.alzforum.orgCategories: General Medicine News, NeurologyTweet-
There’s no doubt that anti-amyloid will increase health discrepancy - the discussion is about the next steps. Great discussion on Leqembi, UK, Japan and the recent European decision: https://t.co/3EMgVD0RPL
-
-
Mashup Score: 1Questions, Questions for Donanemab, Lecanemab | ALZFORUM - 8 month(s) ago
As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association International Conference, held last month in Philadelphia, offered a glimpse at some answers. For the FDA-approved donanemab, it appears that baseline amyloid load best predicts when to stop dosing, and that it may tell the doctor what the right time point might be to confirm with a second PET scan that the
Source: www.alzforum.orgCategories: General Medicine News, Hem/OncsTweet-
RT @EWidera: @ajlees Asked by many. Presented by none https://t.co/3ZB21sYLLg https://t.co/LqRdmTjXZv
-
-
Mashup Score: 6C1q from Microglia Meddles in Neuronal Translation | ALZFORUM - 10 month(s) ago
The innate immune protein C1q seems to have a thing for neurons. Already implicated in synaptic pruning by microglia, now it is reported to also slow down protein production in neurons of the aging mouse brain. In the June 24 Cell, researchers led by Nicole Scott-Hewitt and Beth Stevens at Boston Children’s Hospital reported that microglial C1q infiltrated neuronal ribosomes in year-old mice. In vitro, C1q and RNA formed liquid droplets, hinting that C1q sequesters transcripts in the brain in a process
Source: www.alzforum.orgCategories: General Medicine News, NephrologyTweet-
Nice story on Alzforum on Nicoles paper! Appreciate the feedback and comments https://t.co/QuxcMLPRc8
-
-
Mashup Score: 26
Cross-sectional autopsy studies have suggested that, in Alzheimer’s disease, neurofibrillary tangles first appear in the locus coeruleus (LC) of the brainstem. Now, a longitudinal imaging study lends support to that theory. In the April 25 Nature Aging, scientists led by Jorge Sepulcre at Yale University in New Haven, Connecticut, and Heidi Jacobs of Massachusetts General Hospital, Boston, reported that LC degeneration seen on MRI, a proxy for tangles there, precedes tau PET positivity in the medial
Source: www.alzforum.orgCategories: General Medicine News, NeurologyTweet-
Great discussion on our latest work!! So exciting to see the interest in this field growing 🩵🔵. Very grateful to @TharickAPascoal , @grinberg_t @LCneuroscience @alexa_pichetb @csabaadori and Elliott Mufson for the excellent comments on our work. https://t.co/dzRglox6VP https://t.co/6IXNkNOwEy
-
-
Mashup Score: 0Meningeal interleukin-17-producing T cells mediate cognitive impairment in a mouse model of salt-sensitive hypertension. | ALZFORUM - 1 year(s) ago
Santisteban MM, Schaeffer S, Anfray A, Faraco G, Brea D, Wang G, Sobanko MJ, Sciortino R, Racchumi G, Waisman A, Park L, Anrather J, Iadecola C.. Nat Neurosci. 2023 Dec 4; PubMed. Please login to recommend the
Source: www.alzforum.orgCategories: General Medicine News, General HCPsTweet-
#Meningeal interleukin-17-producing #Tcells mediate cognitive impairment in a mouse model of salt-sensitive #hypertension. https://t.co/AmIOEmLYf7 #IL17 #arachnoid #cognition #bloodpressure #CSF Molecular anatomy of adult mouse #leptomeninges https://t.co/DiXSP03Wm5… https://t.co/CrFOdQvc4D https://t.co/4Yjh9xpGcs
-
-
Mashup Score: 7
The astonishing case of Aliria Rosa Piedrahita de Villegas captivated scientists because she was spared the wrath of her Paisa presenilin 1 mutation. She staved off dementia for three decades longer than her kin and had few neurofibrillary tangles, mild hippocampal neurodegeneration, and minimal neuroinflammation despite a high amyloid plaque load (Sep 2022 conference news). Piedrahita de Villegas carried two copies of a rare APOE3 variant called Christchurch. Was this really to thank for her delayed
Source: www.alzforum.orgCategories: General Medicine News, NeurologyTweet-
Check out my thoughts at the end of this: APOE Christchurch Variant Tames Tangles and Gliosis in Mice. Great story @alzforum on papers by the Huang Lab and @holtzman4 Lab. Protective APOE missense variants are very rare and exceedingly important! https://t.co/PrWRDiBREF
-
RT @LEAD_Coalition: New Partnership Forms to Harness #AI for #Alzheimers Research https://t.co/h8LhmQK78Q by @alzforum #dementia #Artifici…